Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender, with a type of B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment
• People whose doctors estimate they are likely to live for more than 12 weeks
• People with a general health status rated as reasonably functional (a standard medical scoring system rates this as 0–2, meaning the person can largely care for themselves — confirm with trial site)
• People whose lymphoma has been confirmed by a tissue or cell sample as one of these specific types: diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), or high-grade B-cell lymphoma (HGBCL)
• People who meet at least one of the following treatment history conditions: (1) the lymphoma came back or stopped responding after standard first-line treatment and at least two rounds of second-line treatment, and prior treatment must have included drugs targeting CD20 and a type of chemotherapy called anthracyclines; or (2) the lymphoma came back after a stem cell transplant, regardless of what other treatments were received
• People whose blood counts and veins are suitable for a cell collection procedure, with minimum levels of haemoglobin, white blood cells, and platelets meeting specific thresholds (confirm exact values with trial site)
• People who have at least one measurable area of lymphoma that can be tracked using standard imaging guidelines
• People whose kidney, liver, and heart and lung function meet specific minimum thresholds set by the trial, including adequate kidney function, heart pumping function above 50%, blood oxygen levels above 92%, and liver enzyme and bilirubin levels within acceptable ranges (confirm exact values with trial site)
• People who are able to understand and sign a consent form agreeing to participate

Who may not be able to join:

• People who have had a different type of cancer (other than the four lymphoma types listed above) within the past five years, unless it was a specific type that was fully treated, such as certain skin cancers, cervical cancer in situ, localised prostate cancer, ductal carcinoma in situ, or thyroid cancer — all after complete surgical removal
• People with active hepatitis B, hepatitis C, HIV, or syphilis infections detected through blood tests
• People with serious uncontrolled conditions such as active infections, uncontrolled chest pain, a stroke or mini-stroke within the past six months, a heart attack within the past six months, severe heart failure, serious heart rhythm problems requiring medication, or significant liver, kidney, or metabolic disease
• People with any other serious uncontrolled medical condition that the trial team believes would make participation unsafe
• People whose situation the trial investigators believe could put them at risk or interfere with the trial's goals
• Women who are pregnant or breastfeeding, people planning a pregnancy during treatment or within one year after treatment, or male participants whose partner plans to become pregnant within one year after the cell infusion
• People who have had an active or uncontrolled infection requiring full-body (systemic) treatment within the 14 days before joining the trial, except for straightforward urinary tract or upper respiratory infections
• People who have been taking systemic steroid medications in the 14 days before joining and are expected to need them long-term during the trial (inhaled or topical steroids are generally acceptable — confirm with trial site), or people who have recently received any systemic anti-cancer treatment (other than localised treatments)
• People who have previously received CAR-T cell therapy or any other gene-modified cell therapy
• People who have symptoms affecting the brain or central nervous system from their lymphoma, or who have had brain or central nervous system treatment (such as radiotherapy or surgery) within the three months before joining
• People who are unable or unwilling to follow the study procedures, or whose condition affects their ability to provide informed consent
• People whom the trial investigators consider unsuitable for the trial for any other reason

Important: Always verify eligibility with the trial site directly before applying.